Correlation Between CEUS Identification of Nodular HPD on CE-MRI and Hepatic Malignant Lesions

Hepatic malignant tumors are a category of diseases with high incidence and mortality rates worldwide, including various types such as primary hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and liver metastases. With the advancement of imaging technology, the number of hepatic perfusion disorders (HPD) detected in high-risk population screening and follow-up has gradually increased. However, the imaging manifestations of these HPD are highly heterogeneous, and the imaging features of some benign lesions (such as post-treatment inflammatory reactions, arterioportal shunts, hyperplastic nodules, focal fat deposition or fibrotic nodules) overlap with those of malignant lesions, posing a challenge to accurate diagnosis. Therefore, how to improve the ability to distinguish the benign and malignant nature of HPD based on multimodal imaging technology and optimize the follow-up management of high-risk populations has significant clinical value.

Sex

All

Inclusion Criteria:

* Prospective cohort patients voluntarily sign the informed consent form.
* Patients with a history of malignant tumors, CE-MRI indicated the presence of HPD in the liver.
* The shape of HPD is nodular.
* The diameter of HPD is greater than 10mm.
* The main large vessels in the liver are clearly displayed in the MRI.

Exclusion Criteria:

* Patients who unable to complete imaging examinations, such as severe cardiac insufficiency, severe renal insufficiency, hypersensitivity to contrast agents or adverse reactions to them, etc.
* Patients with the history of extensive liver resection or liver transplantation.
* Patients whose abdomen with abundant intestinal gas.